Biotech company Nutri Pharma has been awarded a patent by the US authorities to protect the composition of its staple soy product. The company, which manufactures many products relying on a soy basis, has also posted higher than anticipated operating costs due to marketing and preparations for future product launches. They also revealed a widening of Q3 pre-tax loss, which has reached NKr9.3m from 1999’s figure of NKr0.8m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
